"There are only a handful of people in the world who have experience in running a direct-to-consumer genetic testing company — and I am one of them," Anne Wojcicki said.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday. WHY IT